Immunotherapy in Extensive Stage Small-Cell Lung Cancer in First-Line and Second-Line Setting
ICIs conferred efficacy benefits and an acceptable safety profile in the treatment of patients with ES-SCLC in the first-line, but should not be used in the second-line as single agents. Biomarkers predicting long-term benefit are needed to further improve outcomes.
Authors
- Jacques Raphael (ORCID: https://orcid.org/0000-0002-9484-0224)
- Patsy Lee (ORCID: https://orcid.org/0000-0002-4890-125X)
- Phillip Blanchette (ORCID: https://orcid.org/0000-0001-8865-0996)
- Gabriel Boldt (ORCID: https://orcid.org/0000-0002-8356-6338)
- Nupur Krishnan
- Saurav Verma (ORCID: https://orcid.org/0000-0002-8841-9820)
- Suganija Lakkunarajah
Institutions
- Western University (CA)
- BC Cancer Agency (CA)
- London Health Sciences Centre (CA)
- Mount Vernon Cancer Centre (GB)
- Hamilton Health Sciences (CA)
- McMaster University (CA)
Publication Details
- Journal
- American Journal of Clinical Oncology
- Published
- 2025-12-09
- DOI
- https://doi.org/10.1097/coc.0000000000001265
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00